Production (Stage)
CytomX Therapeutics, Inc.
CTMX
$2.75
-$0.24-8.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 33.66% | 13.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 33.66% | 13.94% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 33.66% | 13.94% | |||
| SG&A Expenses | 67.64% | -29.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 38.61% | -30.38% | |||
| Operating Income | 27.95% | 330.04% | |||
| Income Before Tax | 24.55% | 226.69% | |||
| Income Tax Expenses | 0.00% | 1.64% | |||
| Earnings from Continuing Operations | 24.63% | 229.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.63% | 229.08% | |||
| EBIT | 27.95% | 330.04% | |||
| EBITDA | 27.16% | 298.50% | |||
| EPS Basic | 22.67% | 226.56% | |||
| Normalized Basic EPS | 22.61% | 223.94% | |||
| EPS Diluted | 22.67% | 226.56% | |||
| Normalized Diluted EPS | 22.61% | 224.71% | |||
| Average Basic Shares Outstanding | 1.61% | 0.76% | |||
| Average Diluted Shares Outstanding | 1.64% | 0.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||